Infectious Disease Testing Market Future Outlook and Forecast Report (2026–2034)

July 02, 2026

Infectious Disease Testing Market

The Infectious Disease Testing Market is experiencing strong expansion driven by the rising global burden of infectious diseases, increasing demand for early diagnosis, and advancements in molecular diagnostic technologies. The market size was valued at USD 28 billion in 2025 and is projected to grow from USD 30 billion in 2026 to USD 60 billion by 2034, registering a CAGR of 7% during the forecast period (2026–2034). Growing awareness about preventive healthcare, rapid adoption of point-of-care testing, and continuous innovation in diagnostic platforms are further accelerating market growth across developed and emerging economies.

For detailed market insights, growth forecasts, and competitive analysis, visit: https://straitsresearch.com/report/infectious-disease-testing-market

The increasing prevalence of diseases such as tuberculosis, HIV, hepatitis, influenza, and emerging viral infections has intensified the need for accurate and rapid diagnostic solutions. Additionally, the global healthcare system’s shift toward decentralized testing and personalized medicine is significantly boosting the adoption of advanced infectious disease testing technologies.

Market Drivers

Rising Global Burden of Infectious Diseases

One of the primary growth drivers of the infectious disease testing market is the increasing prevalence of infectious diseases worldwide. Factors such as urbanization, global travel, climate change, and population density contribute to the rapid spread of pathogens. This has led to a growing demand for reliable diagnostic solutions capable of early detection and disease monitoring.

Advancements in Molecular Diagnostics

Technological innovations in polymerase chain reaction (PCR), next-generation sequencing (NGS), and immunoassays have significantly improved diagnostic accuracy and speed. These advancements enable healthcare providers to detect infections at earlier stages, reducing transmission risks and improving treatment outcomes. Molecular diagnostics is increasingly becoming the gold standard in infectious disease detection.

Growing Adoption of Point-of-Care Testing

Point-of-care testing (POCT) is gaining widespread acceptance due to its convenience, rapid results, and ability to be used in remote or resource-limited settings. These systems reduce dependency on centralized laboratories and help in timely decision-making, especially during outbreaks and pandemics.

Increasing Government and Healthcare Investments

Governments and healthcare organizations are investing heavily in strengthening diagnostic infrastructure. Initiatives aimed at disease surveillance, pandemic preparedness, and public health safety are driving the deployment of advanced infectious disease testing systems globally.

Market Challenges

High Cost of Advanced Diagnostic Systems

Despite technological advancements, high costs associated with molecular diagnostic platforms and automated testing systems remain a major challenge. Smaller healthcare facilities and developing regions often face budget constraints, limiting widespread adoption.

Limited Access in Low-Income Regions

In many low- and middle-income countries, inadequate healthcare infrastructure and limited laboratory facilities restrict access to advanced infectious disease testing. This creates disparities in diagnosis and treatment outcomes across regions.

Regulatory and Approval Complexities

Strict regulatory frameworks governing diagnostic test approvals can delay product launches. Companies must comply with multiple quality and safety standards, which increases development timelines and operational costs.

Market Segmentation

By Test Type

The infectious disease testing market is segmented into:

Molecular Diagnostics
Immunoassays
Rapid Diagnostic Tests
Culture-Based Tests
Others

Among these, Molecular Diagnostics dominates the market due to its high accuracy, sensitivity, and ability to detect pathogens at the genetic level. Meanwhile, Rapid Diagnostic Tests are expected to grow the fastest due to increasing demand for quick and accessible testing solutions.

By Disease Type

Key segments include:

HIV/AIDS
Tuberculosis
Hepatitis
Influenza
Sexually Transmitted Infections (STIs)
Hospital-Acquired Infections
Emerging Infectious Diseases

HIV/AIDS and Tuberculosis testing continue to account for a significant market share due to their global prevalence. However, emerging infectious diseases are witnessing rapid growth, especially in the wake of global outbreaks and increased surveillance efforts.

By End User

Major end users include:

Hospitals & Clinics
Diagnostic Laboratories
Academic & Research Institutes
Point-of-Care Settings

Hospitals and diagnostic laboratories remain the largest end users due to high patient inflow and availability of advanced testing infrastructure. Meanwhile, point-of-care settings are growing rapidly with the expansion of decentralized healthcare services.

Regional Insights

North America

North America leads the infectious disease testing market due to advanced healthcare infrastructure, strong presence of key diagnostic companies, and high awareness regarding early disease detection. The United States continues to dominate the region with extensive investments in molecular diagnostics and public health surveillance systems.

Europe

Europe holds a significant market share driven by strong government support for healthcare innovation and well-established diagnostic networks. Countries such as Germany, France, and the United Kingdom are investing in advanced testing technologies and infectious disease control programs.

Asia-Pacific

Asia-Pacific is expected to register the fastest growth during the forecast period. Rapid population growth, increasing disease burden, improving healthcare infrastructure, and rising government initiatives in countries like China, India, and Japan are driving market expansion. Growing awareness of preventive healthcare is also boosting demand for diagnostic services.

Latin America, Middle East & Africa

These regions are witnessing steady growth due to improving healthcare infrastructure and increasing investments in disease surveillance systems. However, limited access to advanced diagnostic tools in rural areas remains a challenge. International collaborations and public health programs are expected to improve market penetration.

Key Players Analysis

The infectious disease testing market is highly competitive, with leading companies focusing on innovation, strategic partnerships, and expansion of diagnostic portfolios. Continuous investment in molecular diagnostics, automation, and rapid testing technologies is shaping the competitive landscape.

Major companies operating in the market include:

Abbott Laboratories
Roche Diagnostics
Thermo Fisher Scientific
Danaher Corporation
bioMérieux SA
Siemens Healthineers
Becton, Dickinson and Company (BD)
Qiagen N.V.
Hologic Inc.
Sysmex Corporation
QuidelOrtho Corporation
Luminex Corporation
Cepheid (Danaher)
Grifols S.A.
Illumina Inc.

Conclusion

The Infectious Disease Testing Market is poised for strong growth, supported by rising disease prevalence, technological advancements, and increasing demand for rapid and accurate diagnostic solutions. With the market expected to grow from USD 30 billion in 2026 to USD 60 billion by 2034, at a CAGR of 7%, the industry is undergoing significant transformation. While challenges such as high costs and limited access in developing regions persist, ongoing innovation and government initiatives are expected to create substantial opportunities for market expansion in the coming years.

About Us

Straits Research is a leading market research and intelligence organization specializing in research, analytics, and advisory services. The company provides comprehensive market reports, industry insights, and strategic business intelligence across multiple industries, helping organizations identify growth opportunities and make informed business decisions.